Inicure AB

Inicure AB is a Swedish biotech company developing a new class of immune-activating therapies to combat antibiotic-resistant infections. Our innovative small-molecule FPR1 agonists boost the body’s own immune response—offering a resistance-free alternative to traditional antibiotics. Founded in 2024 as a spin-off from Pronoxis AB and GU Ventures, Inicure is advancing promising preclinical compounds with strong efficacy and safety profiles, supported by leading academic and industry partners.